# A Clinical Trial of TQB3117 Tablets in Patients With Advanced Malignant Cancer

> **NCT06415903** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 59 (estimated)

## Conditions studied

- Advanced Malignant Cancer

## Interventions

- **DRUG:** TQB3117 tablets

## Key facts

- **NCT ID:** NCT06415903
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-06
- **Primary completion:** 2025-06
- **Final completion:** 2026-08
- **Target enrollment:** 59 (ESTIMATED)
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06415903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06415903, "A Clinical Trial of TQB3117 Tablets in Patients With Advanced Malignant Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06415903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*